Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
FRONTIERS IN ENDOCRINOLOGY(2022)
摘要
Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.
更多查看译文
关键词
pasireotide,refractory hypoglycemia,neuroendocrine tumor,pancreatic neuroendocrine cancer,malignant insulinoma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要